W&T Announces Addition to Its Board of Directors
01 Mayo 2023 - 5:45AM
W&T Offshore, Inc. (NYSE: WTI) (“W&T” or the “Company”)
today announced that Dr. Nancy Chang was appointed as a new
independent director to the Company’s Board of Directors. Dr. Chang
will serve as a member of the Audit Committee and the Nominating
and Corporate Governance Committee and as the chair of the
Environmental, Safety and Governance (“ESG”) Committee. She will
stand for election at the Company’s upcoming annual meeting of
shareholders.
Tracy W. Krohn, W&T’s Board Chair and Chief
Executive Officer stated, “We are very pleased to welcome Nancy to
our Board of Directors. She is a a widely respected and
internationally recognized scientist as well as a highly successful
senior executive in both the private and public sectors. Nancy’s
impressive prior experience as a member of a number of boards of
directors and having served on the Board of the Federal Reserve
Bank in Houston will make her a valuable member of our Board. In
particular, we believe that Nancy’s experiences as founder and
chief executive officer of a successful, publicly-traded company
and one of the largest healthcare-focused investment management
firms in the world bring unique perspectives, talents and insights
to the Board. We are pleased to further increase the diversity of
our Board with Nancy’s appointment, and provide her the opportunity
to lead our ESG Committee where she can use her extensive and
varied experience to assist us in our commitment to the highest
standards of ESG and corporate governance.”
About Dr. Chang
Dr. Nancy Chang is currently serving as a member
of the board of directors of Ansun Biopharma, Inc., a clinical
late-stage biopharmaceutical company, where she was the Chief
Executive Officer from March 2017 until July 2022. In addition to
her role with Ansun Biopharma, Inc., she has also served as the
Chair and Founder of Apex Capital, an investment management company
focused on investments in healthcare, education and socially
responsible ventures, since January 2009, and has served as
President of the Tang Family Foundation since March 2009. Dr. Chang
also served on the board of directors of Helix Acquisition Corp.
from October 2020 until April 2022. From 2007 to 2012, Dr. Chang
was the Founder, Chair and Senior Managing Director of Caduceus
Asia Partners at OrbiMed Advisors L.L.C. Prior to that, Dr. Chang
was the Co-Founder, President, Chief Executive Officer and Chair of
Tanox, Inc. from 1986 to 2006, where she led the company through an
initial public offering in 2000 and growth to a $1 billion public
valuation until its acquisition by Genentech Inc. in 2007. From
1980 to 1986, Dr. Chang held several leadership positions at
Centocor Biotech Inc., where she served as Director of Research. In
addition, Dr. Chang has served on the boards of several other
companies, including Charles River Laboratory International, Inc.,
Eddingpharm (Cayman) Inc., Crown Bioscience Inc., Applied
Optoelectronics, Inc., SciClone Pharmaceuticals, Inc., BIO, and
BioHouston and a number of other private companies. She has also
previously served on the board of directors of the Federal Reserve
Bank in Houston.
Throughout her career, she received numerous
awards from academic, industrial, national and international
organizations. She was named the Most Respected Woman in
Biotechnology in 2005, Forbes Twenty-Five Notable Chinese Americans
list in 2008 and was the first woman to receive the Biotechnology
Heritage Award in 2012. She has published more than 35 papers on
topics ranging from monoclonal antibodies to human immunodeficiency
virus (HIV) and holds seven patents. Dr. Chang graduated from
National Tsing Hua University in Taiwan and Brown University and
received her Ph. D. from the Division of Medical Sciences at
Harvard Medical School in 1979.
About W&T Offshore
W&T Offshore, Inc. is an independent oil and
natural gas producer, active in the exploration, development and
acquisition of oil and natural gas properties in the Gulf of
Mexico. As of December 31, 2022, the Company holds working
interests in 47 offshore fields in federal and state waters (45
fields producing and 2 fields capable of producing, which include
39 fields in federal waters and 8 in state waters). The Company
currently has under lease approximately 625,000 gross acres
(457,000 net acres) spanning across the outer continental shelf off
the coasts of Louisiana, Texas, Mississippi and Alabama, with
approximately 8,000 gross acres in Alabama State waters, 458,000
gross acres on the conventional shelf and approximately 159,000
gross acres in the deepwater. A majority of the Company’s daily
production is derived from wells it operates. For more information
on W&T, please visit the Company’s website at
www.wtoffshore.com.
CONTACT: |
Al Petrie |
|
Investor Relations Coordinator |
|
investorrelations@wtoffshore.com |
|
713-297-8024 |
W and T Offshore (NYSE:WTI)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
W and T Offshore (NYSE:WTI)
Gráfica de Acción Histórica
De May 2023 a May 2024